Abstract
Menogaril, a semisynthetic anthracycline antibiotic, was administered to patients with metastatic adenocarcinoma of the prostate. Forty-five patients with measurable disease and 45 patients with evaluable disease received 150–200 mg/m2 over 1 hour every 28 days. There were three partial responses (PR) among 87 patients evaluable for response. Myelosuppression was dose limiting. There were two deaths related to leukepenia. Other toxicities included phlebitis, alopecia, nausea and vomiting. One patient developed acute nonlymphocytic leukemia.
Menogaril at these doses and schedule is toxic and has no signficant antitumor activity in metastatic adenocarcinoma of the prostate.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Neil GL, Kuentzel SL, McGovern JP: Treatment of mouse tumors with 7-con-o-methylenogariel and other analogs of the anthracycline antibiotics, nogalamycin. Cancer Treat Rep 63:1971–1978, 1979
Dodion P, Sessa C, Joss R, Crespeigne N, Williams Y, Kitt M, Adams WJ, Finet C, Brewer JE, Adams WJ, Earhart RH, Rozencweig M, Kenis Y, Cavalli F: Phase I study of intravenous menogaril administered intermittently. J Clin Oncol 4:767–774, 1986
Dorr FA, Van Hoff DD, Kuhn JG, Schwartz R, Kisnor DL: Phase I clinical investigation of 7-con-o-methylnogaril, a new anthracycline antibiotic. Cancer Res 46: 2562–2565, 1986
Sigman LM, Van Echo DA, Egorin MJ, Whitacre MY, Aisner J: Phase I trial of menogaril administered as an intermittent daily infusion for 5 days. Cancer Treat Rep 70:721–725, 1986
Fleming TR: One-sample multiple testing procedures for phase II clinical trials. Biometrics 38:143–151, 1982
Yagoda A, Watson RC, Natale RB et al.: A critical analysis of response criteria in patients with prostatic cancer treated with cis-diamine dichloride platinum II. Cancer 44:1553–1562, 1976
Eagan RT, Hahn RG, Myers RP: Adriamycin (NSC-123127) versus 5-fluorouracil (NSC-19893) and cyclophosphamide (NSC 26271) in the treatment of metastatic prostate cancer. Cancer Treat Rep 60:115–117, 1976
Schmidt JD, Johnson DE, Scott WW, Gibbons RP, Prout GR Jr, Murphy GP: The National Prostatic Cancer Project: Chemotherapy of advanced prostatic cancer, evaluation of response parameters. Urology 7:602–610, 1976
DeWys WD, Bauer M, Colsky J, Cooper RA, Creech R, Carbone PP: Comparative trial of Adriamycin and 5-fluorouracil in advanced prostatic cancer: Progress report. Cancer Treat Rep 61:325–328, 1977
Slack NH, Bross IDJ: The influence of site of metastasis on tumor growth and response to chemotherapy. Br J Cancer 32:78–86, 1975
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Taylor, S.A., Blumenstein, B.A., Stephens, R.L. et al. Phase II trial of menogaril in metastatic adenocarcinoma of the prostate. Invest New Drugs 12, 67–70 (1994). https://doi.org/10.1007/BF00873240
Issue Date:
DOI: https://doi.org/10.1007/BF00873240